Login to Your Account


PharmaFocus

AstraZeneca's CEO Exits as Firm Enters Patent Cliff Free Fall

By Nuala Moran
Staff Writer

Wednesday, May 2, 2012
LONDON – AstraZeneca plc is expected to boost dealmaking and M&A activity after CEO David Brennan gave in to pressure from shareholders last week and agreed to resign his post.

To continue reading subscribe now to BioWorld International

Learn More about BioWorld International

Already a subscriber? Sign In or Buy now to activate your subscription


»

BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Privacy Policy | Terms of Use
 
Part of Thompson Media Group LLC

Free Ezine

Sign up for Perspectives FREE e-mail newsletter.

Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.